RxDoctor Payments Data

Paul Diamond, DO

Family Medicine · Boca Raton, FLNPI 1427032796

Payments from drug & device makers

$7,997in general payments, 2019–2025

Across 394 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$834
  • GSK$616
  • Pfizer$590
  • Johnson & Johnson$560
  • Amarin Pharma, Inc.$399
  • plus $4K from 42 others

What the payments were for

  • Consulting fees$130%
  • Food & beverage$7,984100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,997 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$387,498
Medicare patients
423
Services billed
12,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$71,813
OzempicSemaglutide50$48,839
XareltoRivaroxaban24$30,039
EliquisApixaban21$28,678
MounjaroTirzepatide26$27,410
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$24,971
EntrestoSacubitril/Valsartan17$21,819
Repatha SureclickEvolocumab23$14,832
FarxigaDapagliflozin Propanediol11$9,469
SynthroidLevothyroxine Sodium61$6,056
Atorvastatin Calcium363$2,914
Ezetimibe106$2,601
Rosuvastatin Calcium238$2,479
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen67$2,332
Testosterone Cypionate31$2,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$119$71,81379 claims
Novo NordiskOzempic$155$48,83950 claims
Johnson & JohnsonXarelto$560$30,03924 claims
PfizerEliquis$590$28,67821 claims
Lilly USA, LLCMounjaro$166$27,41026 claims
GSKTrelegy Ellipta$616$24,97127 claims
NovartisEntresto$342$21,81917 claims
AstraZenecaFarxiga$197$9,46911 claims
AbbVieSynthroid$834$6,05661 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →